Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q4 2025 value amounting to $488.9 million.

  • Vanda Pharmaceuticals' Liabilities and Shareholders Equity fell 2548.84% to $488.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.3 billion, marking a year-over-year decrease of 992.57%. This contributed to the annual value of $488.9 million for FY2025, which is 2548.84% down from last year.
  • According to the latest figures from Q4 2025, Vanda Pharmaceuticals' Liabilities and Shareholders Equity is $488.9 million, which was down 2548.84% from $601.1 million recorded in Q3 2025.
  • In the past 5 years, Vanda Pharmaceuticals' Liabilities and Shareholders Equity ranged from a high of $656.2 million in Q4 2024 and a low of $488.9 million during Q4 2025
  • Over the past 5 years, Vanda Pharmaceuticals' median Liabilities and Shareholders Equity value was $628.3 million (recorded in 2025), while the average stood at $614.1 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first surged by 1237.86% in 2021, then crashed by 2548.84% in 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' Liabilities and Shareholders Equity (Quarter) stood at $593.8 million in 2021, then grew by 6.81% to $634.2 million in 2022, then grew by 2.24% to $648.4 million in 2023, then grew by 1.2% to $656.2 million in 2024, then fell by 25.49% to $488.9 million in 2025.
  • Its last three reported values are $488.9 million in Q4 2025, $601.1 million for Q3 2025, and $624.7 million during Q2 2025.